<DOC>
	<DOCNO>NCT01942109</DOCNO>
	<brief_summary>The aim study compare effect torasemide furosemide clinical biochemical parameter hemodynamic neurohormonal compensation myocardial remodel patient chronic heart failure indication use loop diuretic . The study protocol 100 patient heart failure NYHA ( New York Heart Association ) II-IV ( stable exacerbation align cardiopulmonary time enrollment , fixed-dose loop diuretic ] ) treat optimal medical therapy clinically indicate use loop diuretic . Patients randomize treatment furosemide torasemide ( randomization 1 : 1 ) . After randomization , furosemide continue current fixed-dose replace equipotential dose torasemide ( 4:1 ) . The minimal follow-up patient study least six month .</brief_summary>
	<brief_title>The Impact TORasemide oN hemodynAmic Neurohormonal Stress , carDiac remOdeling Heart Failure</brief_title>
	<detailed_description>According current guideline , angiotensin convert enzyme inhibitor beta-adrenolytics first-line treatment agent patient heart failure . In case fluid retention , diuretic , part symptomatic treatment , administer . In practice , common diuretic use patient heart failure loop diuretic - furosemide . What important , furosemide effect patient ' outcome . Some study show unfavourable influence drug rennin-angiotensin-aldosterone system . Alternative loop diuretic , may administer patient heart failure torasemide . Its long elimination half-life time , similar diuretic effect , low influence electrolyte disorder additional pleiotropic effect could make torasemide beneficial furosemide . Accordingly , direct comparison furosemide torasemide could present similarity differences two agent . The hypothesis study torasemide may present favourable effect clinical parameter patient heart failure , furosemide ( e.g . clinical symptom , biochemical parameter , activity rennin-angiotensin-aldosterone system , side effect ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Torsemide</mesh_term>
	<criteria>heart failure NYHA IIIV previous treatment diuretic age &gt; 18 year uncontrolled hypertension uncontrolled diabetes creatinine &gt; 2,5 mg/dl potassium &gt; 6 mg/dl acute coronary syndrome hypertrophic cardiomyopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>heart failure</keyword>
	<keyword>diuretic</keyword>
	<keyword>furosemide</keyword>
	<keyword>torasemide</keyword>
</DOC>